Advertisement
Research Article Free access | 10.1172/JCI114773
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Find articles by Harata, N. in: JCI | PubMed | Google Scholar
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Find articles by Sasaki, T. in: JCI | PubMed | Google Scholar
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Find articles by Osaki, H. in: JCI | PubMed | Google Scholar
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Find articles by Saito, T. in: JCI | PubMed | Google Scholar
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Find articles by Shibata, S. in: JCI | PubMed | Google Scholar
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Find articles by Muryoi, T. in: JCI | PubMed | Google Scholar
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Find articles by Takai, O. in: JCI | PubMed | Google Scholar
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Find articles by Yoshinaga, K. in: JCI | PubMed | Google Scholar
Published September 1, 1990 - More info
-81 and NE-1 idiotypes (Id) of human nephritogenic anti-DNA antibodies are interspecies Id expressed also in NZB/W F1 mice. We tried to manipulate the synthesis of spontaneously occurring anti-DNA antibody using monoclonal anti-Id antibodies (D1E2 and 1F5) conjugated with a cytotoxic agent, neocarzinostatin (NCS). In vivo administration of anti-Id antibodies conjugated with NCS brought about an improvement in the survival rate of female NZB/W F1 mice. It also caused a retardation of development of lupus nephritis and decreased the numbers of anti-DNA-producing cells. The suppression of anti-DNA antibody synthesis was specific and Id-mediated. The results indicate that the use of a limited number of anti-Id antibodies in combination with a cytotoxic agent may be applicable therapeutically to autoimmune diseases.
Images.